E2F2

Across TCGA pan-cancer cohorts, E2F2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated E2F2 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher E2F2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated E2F2 expression acts as an unfavorable survival marker.

CESC, SARC, and LGG are the cancer types where E2F2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
LGG	DFS	Median	All	0.201	0.738	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

E2F2–CESC (OS)

Open the CESC breakdown →